Skip to content
10-Q

Quarterly Report

INTELLIA THERAPEUTICS, INC. NTLA

0001193125-26-215740

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 139.72M sh
Stock Issued Q1 2026 · Apr 28, 2026 16.74M sh
Shares Diluted Q1 2026 · Mar 31, 2026 118.49M sh
Shares Diluted Q1 2026 · Mar 31, 2025 103.5M sh
Capex Q1 2026 · Mar 31, 2026 $79K
Capex Q1 2026 · Mar 31, 2025 $735K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$117.35M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$148.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $134.7M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $155.46M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $126.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $620.94M
Stockholders Equity Q1 2026 · Dec 31, 2025 $671.39M
Stockholders Equity Q1 2026 · Mar 31, 2025 $779.92M
Stockholders Equity Q1 2026 · Dec 31, 2024 $871.96M
Current Liabilities Q1 2026 · Mar 31, 2026 $76.45M
Current Liabilities Q1 2026 · Dec 31, 2025 $103.88M
Total Liabilities Q1 2026 · Mar 31, 2026 $137.84M
Total Liabilities Q1 2026 · Dec 31, 2025 $170.73M
Current Assets Q1 2026 · Mar 31, 2026 $466.45M
Current Assets Q1 2026 · Dec 31, 2025 $527.71M
Total Assets Q1 2026 · Mar 31, 2026 $758.78M
Total Assets Q1 2026 · Dec 31, 2025 $842.13M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.81
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.10
Eps Basic Q1 2026 · Mar 31, 2026 −$0.81
Eps Basic Q1 2026 · Mar 31, 2025 −$1.10
Sga Expense Q1 2026 · Mar 31, 2026 $34.84M
Sga Expense Q1 2026 · Mar 31, 2025 $29.01M
Rd Expense Q1 2026 · Mar 31, 2026 $80.74M
Rd Expense Q1 2026 · Mar 31, 2025 $108.43M
Net Income Q1 2026 · Mar 31, 2026 −$96.23M
Net Income Q1 2026 · Mar 31, 2025 −$114.33M
Operating Income Q1 2026 · Mar 31, 2026 −$100.53M
Operating Income Q1 2026 · Mar 31, 2025 −$120.81M
Revenue Q1 2026 · Mar 31, 2026 $15.05M
Revenue Q1 2026 · Mar 31, 2025 $16.63M